FINWIRES · TerminalLIVE
FINWIRES

$HAE

3 stories mentioning HAEUpdated 24d ago

Every FINWIRES story that references HAE, newest first.

Sectors

Sector Update: Healthcare Stocks Higher Late Afternoon

Healthcare stocks rose late Friday afternoon with the NYSE Healthcare Index increasing 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.7%.The iShares Biotechnology ETF (IBB) declined 1.6%.In corporate news, Haemonetics (HAE) updated its financial reporting structure and will transition to two segments from three starting in Q1 fiscal 2027. The stock rose 1.8%.BioCardia (BCDA) received confirmation from the US Food and Drug Administration that its ongoing trial may support a premarket approval of the CardiAMP Cell Therapy System for the treatment of ischemic heart failure with reduced ejection fraction. BioCardia shares climbed 23%.CareCloud (CCLD) said shareholders approved all proposals put forward at the annual investor meeting on Thursday, including the re-election of Mahmud Haq and Cameron Munter to the board. CareCloud shares fell 1.5%.Vivos Therapeutics (VVOS) entered a deal with its senior secured lender, Streeterville Capital, to exchange up to $4.5 million of its outstanding debt for a combination of perpetual, nonconvertible preferred stock and shares. Vivos shares climbed 27%.

$BCDA$CCLD$HAE$VVOS
Wire

Haemonetics Likely to See Upside as Core Businesses Improve, BofA Securities Says

Haemonetics (HAE) is positioned for potential upside as the company has issued conservative fiscal 2027 guidance across its core segments Plasma, Hospital, and Blood Center, BofA Securities said in a note Friday.Analysts highlighted strong plasma collection trends, with US volumes rising high single digits in fiscal Q4, indicating potential upside if momentum continues.In the Hospital segment, the investment firm said vascular closure is improving with stronger commercial execution and blood management technologies are expected to remain a steady growth driver.Some upside is also likely in the Blood Center segment, where management has guided for a mid-single-digit decline, BofA said.Analysts cited potential catalysts, including Japan label expansion for vascular closure, the Japanese Red Cross plasma transition, possible tariff relief, and new products such as Vivasure's PerQseal Elite, with additional plasma innovation potentially supporting growth beyond 2027.BofA upgraded Haemonetics stock to buy from neutral, and raised its price target to $80 from $72.Shares of Haemonetics were up 2.7% in Friday trading.Price: $63.64, Change: $+1.70, Percent Change: +2.74%

$HAE
Research

BofA Securities Upgrades Haemonetics to Buy From Neutral, Price Target is $80

Haemonetics (HAE) has an average rating of overweight and mean price target of $81, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$HAE

Track with the FINWIRES app suite